Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ACNS0332 carboplatin radiosensitization in high-risk medulloblastoma
NL-OMON21835Phase 3Recruiting
- Sponsor
- SKion
- Start
- Jun 2011
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of carboplatin and isotretinoin in medulloblastoma and primitive neuroectodermal tumor (PNET), sponsored by SKion. Started Jun 2011; status: recruiting.
02
Drugs
carboplatinisotretinoin
03
Conditions
medulloblastomaprimitive neuroectodermal tumor (PNET)
Beyond the preview
Go deeper on NL-OMON21835.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON21835.